Tissue Perfusion and Blood Flow Monitoring Technology

描述（由申请人提供）：需要能够量化组织灌注，以评估缺血组织（如伤口和皮瓣）的活力。对于糖尿病患者的伤口护理，血管生成受损的早期检测是挽救的重要决定因素。这降低了成本，降低了截肢的风险，并提高了患者的满意度。大约10%的皮瓣需要翻修，挽救率约为85%。有效的监测皮瓣将提供早期预警可能并发症的皮瓣手术，并允许早期干预。目前，主观视觉观察仍然通常用于识别和评估移植物和伤口的改善。一个基于激光散斑空间分析的成像仪将作为一个独立的单元开发。该方法采用动态事件的空间平均来从一次曝光获得速度图像的全局图片。在不同曝光下从相同场景获得的图像可以用于提高速度值的准确性。它允许在真实的时间内采集全视野灌注图像。短曝光时间减少了运动伪影的影响。随着美国人口中肥胖率的不断上升，出现了更多的糖尿病病例。所提出的激光散斑成像仪提供了在进行高压氧治疗和/或手术的患者中的组织活力的实时非侵入性监测。它可以减少与皮肤移植物的修改相关的医疗人员的财务成本和身体需求，并通过确定持续HBO治疗的有效性。临床试验后，其商业市场性和应用将更加明显。从该项目中获得的科学，技术和临床知识可用于改进高压氧治疗方案，减少治疗费用和时间。根据疾病控制和预防中心的数据，共有2080万人或7%的美国人口患有糖尿病。2002年，美国糖尿病的估计费用为1320亿美元，约占医疗保健总支出的11%。该项目旨在开发一种先进的、非接触式和非侵入式光学成像仪，以提供糖尿病患者选定伤口区域的血液流速的实时定量测量。

DESCRIPTION (provided by applicant): There is a need to be able to quantify tissue perfusion for the purpose of assessing the viability of ischemic tissue such as wounds and flaps. For wound care in diabetes, early detection of angiogenesis compromise is an important determinant of salvage. This reduces cost, reduces risk of amputation, and increases patient satisfaction. Approximately 10% of all flaps require revision with a salvage rate of approximately 85%. Effective monitoring flaps would provide early warning of possible complications for flap surgery and allow earlier intervention. Currently subjective visual observation is still commonly used to identify the improvement and assessment of grafts and wounds. An imager based on the spatial analysis of laser speckle will be developed as a standalone unit. This method employs spatial averaging of the dynamic events to obtain a global picture of the velocity image from one exposure. Images obtained from the same scene at different exposures can be used to improve accuracy of the velocity values. It allows acquisition of full-field perfusion images in real time. The short exposure time reduces the effects of motion artifacts. W with an increasingly high percentage of obesity in the U.S. population, more diabetic cases have emerged. The proposed laser speckle imager provides real-time noninvasive monitoring of tissue viability in patients undergoing hyperbaric oxygen therapy and/or surgery. It can reduce the financial costs and physical demands on the medical staff associated with the revision of skin grafts and by determining the effectiveness of continued HBO treatment. Its commercial marketability and application will become more apparent after the clinical trial. The scientific, technical, and clinical knowledge gained from this project can be utilized to improve protocols for hyperbaric oxygen therapy, reducing both costs and time of treatment. According to the Centers for Disease Control and Prevention, a total of 20.8 million people or 7% of the U.S. population have diabetes. The estimated diabetes cost in the U.S. in 2002 was $132 billion, about 11% of the total health care expenditure. This project is designed to develop an advanced, noncontact, and noninvasive optical imager to provide real-time, quantitative measurements of blood velocities in the selected wound areas of diabetic patients.